RVMD is the ticker symbol for Revolution Medicines, Inc., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks RVMD with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is RVMD a good stock to buy?

RVMD is tracked on 13F Pro with SEC EDGAR data, but is not currently included in our 32-signal AI quality ranking. The full company profile with financials and AI insights is at https://13fpro.ai/company/RVMD.

Where does 13F Pro source RVMD data?

All Revolution Medicines, Inc. fundamentals and ownership data come directly from SEC EDGAR. Revolution Medicines, Inc. files with the SEC under CIK 1628171. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

Revolution Medicines, Inc.(RVMD)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Revolution Medicines, Inc. (RVMD) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. RVMD is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Revolution Medicines, Inc. reports net income of $-644.4M, free cash flow of $-389.6M. Top institutional holders of RVMD by reported 13-F value include BlackRock, FARALLON CAPITAL MANAGEMENT, FMR, based on the most recent SEC filings. RVMD trades on the Nasdaq exchange and files with the SEC under CIK 1628171. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RVMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Revolution Medicines, Inc. directly from SEC EDGAR.

Net Income

$-644.4M

Free Cash Flow

$-389.6M

RVMD key financials by period

Revolution Medicines, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2023	10-K	$11.6M	$-436.4M	—
FY 2022	10-K	$35.4M	$-248.7M	—
FY 2021	10-K	$29.4M	$-187.1M	—
FY 2020	10-K	$43.0M	$-108.2M	—
FY 2019	10-K	$50.0M	$-47.7M	-108.1%
FY 2018	10-K	$20.2M	$-41.8M	-200.0%

Institutions holding RVMD

Institutional investors reporting a position in Revolution Medicines, Inc. on SEC Form 13F.
Institution	Shares	Value	Reported
BlackRock	13,695,790	$2.6B	2026-06-30
FARALLON CAPITAL MANAGEMENT	13,550,796	$2.5B	2026-06-30
FMR	12,200,422	$2.3B	2026-06-30
BAKER BROS. ADVISORS	11,443,357	$2.1B	2026-06-30
Darwin Global Management, Ltd.	10,629,822	$2.0B	2026-06-30
Jupiter Topco	10,736,145	$2.0B	2026-06-30
VANGUARD CAPITAL MANAGEMENT	9,088,661	$1.7B	2026-06-30
VANGUARD PORTFOLIO MANAGEMENT	8,294,855	$1.6B	2026-06-30
Nextech Invest, Ltd.	7,601,087	$1.4B	2026-06-30
Paradigm Biocapital Advisors	6,361,323	$1.2B	2026-06-30

SEC EDGAR: CIK 1628171 →

Revolution Medicines, Inc.

RVMD

NasdaqLarge CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.